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Abstract: Escherichia coli strains have been modified in a variety of ways to enhance the production of
different recombinant proteins, targeting membrane protein expression, proteins with disulphide
bonds, and more recently, proteins which require N-linked glycosylation. The addition of glycans to
proteins remains a relatively inefficient process and here we aimed to combine genetic modifications
within central carbon metabolic pathways in order to increase glycan precursor pools, prior to transfer
onto polypeptide backbones. Using a lectin screen that detects cell surface representation of glycans,
together withWestern blot analyses using an O-antigen ligase mutant strain, the enhanced uptake and
phosphorylation of sugars (ptsA) from the media combined with conservation of carbon through the
glyoxylate shunt (icl) improved glycosylation efficiency of a bacterial protein AcrA by 69% and over
100% in an engineered human protein IFN-α2b. Unexpectedly, overexpression of a gene involved in
the production of DXP from pyruvate (dxs), which was previously seen to have a positive impact on
glycosylation, was detrimental to process efficiency and the possible reasons for this are discussed.
Keywords: N-glycosylation; Escherichia coli; glycosylation efficiency; cell engineering; recombinant
protein production
1. Introduction
Glycosylation is regarded as one of the most common post-translational modifications of proteins,
occurring on almost half of all proteins in nature [1]. The addition of a sugar group impacts on protein
biophysical properties, which can influence native functions, for example, activity, localisation and
half-life. Although present across all domains of life, eukaryotic systems remain the most characterised
and therefore the best understood. In humans, it is thought that nearly half of all proteins are
modified by the addition of sugars, with 90% of the molecular mass of some glycoproteins made
up by glycans. More recently, a growing interest in prokaryotic glycosylation has led to improved
understanding of the molecular mechanisms involved and the functional traits associated with this
relatively energy-expensive protein modification process. However, overall knowledge is relatively
poor due to the diversity of glycan structures and variability of the processes in prokaryotic systems.
Escherichia coli is a well-established protein production cell factory, which has been exploited
industrially for several decades. From high value therapeutics to high bulk industrial enzymes, E. coli
Bioengineering 2019, 6, 27; doi:10.3390/bioengineering6010027 www.mdpi.com/journal/bioengineering
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strains have beenmodified and refined to create an array of industrial host cell platforms. This is largely
due to its fast growth, cheap cultivation requirements and its easy-to-manipulate genome. Moreover,
the community has been rewarded by its success, meaning that our understanding of the genetic
complexity within strains has improved as it has been widely used as a model system. Although E. coli
is used for the production of a variety of proteins, it can struggle to express certain types. These are
often larger, complex proteins, where multiple transmembrane helices might be present, making
expression difficult. There can also be a need for modifications, for example, disulphide bridges.
Many alterations have been made to the E. coli cell chassis to improve recombinant protein production
to overcome these expression challenges. For example, the well-studied “Walker strains” C41 (DE3)
and C43 (DE3) were generated, which enable relatively high levels of membrane protein expression [2].
The mutated cells accumulate extra membrane space by mutations in their lacUV5 promoter. Similarly,
strains such as CyDisCo or SHuffle are able to express proteins which require bonds between cysteine
groups on amino acid side chains, requiring a reducing environment. CyDisCo cells specifically
utilise the expression of the sulfhydryl oxidase Erv1p and a disulphide isomerase (PDI) [3,4] to enable
efficient bond formation in the cytoplasm, instead of relying on transport to the periplasmic space [5,6].
These strains have since been commercialised.
N-glycosylation involves the addition of glycan structures to the asparagine side chain in
polypeptide structures in cells. This cellular process has been characterised in several Gram-negative
bacteria, mechanistically as well as functionally [7,8]. The functional transfer of the Campylobacter
jejuni protein glycosylation pathway into E. coli predictably led to excitement amongst the recombinant
protein community [9], where E. coli could be used to produce glycoproteins, whether for diagnostics,
therapeutics, or simply as a research tool to better understand the functional attributes of specific
glycoforms. Molecular engineering efforts have demonstrated that E. coli can glycosylate different
proteins, from bacterial to eukaryotic origin [9–11]. Moreover, the sugar structures can be changed,
and the core eukaryotic trimannosyl-chitobiose has been constructed by incorporating different genes
into cells [12,13].
Despite these ambitious efforts to create new N-linked glyco-profiles in E. coli by exploiting the
C. jejuni cellular machinery, the productivity of the system remains relatively poor. Investigations
into how the protein structure affects enzyme access to the N-glycosylation consensus sequence
have revealed optimal surrounding amino acids [14]. Process optimisations include improved gene
expression induction regimes and media formulations [15]. Although proteins are synthesised in a
template-driven process as part of the central dogma of molecular biology, glycans are not. They are
secondary gene products, which are constructed through a series of metabolic steps controlled by
proteins (mostly enzymes) [16]. This is an energetically demanding process and, therefore, E. coli
suffers from a degree of metabolic burden [17]. Efforts to engineer the cells to overcome these
constraints have been systematic, based on the existing body of literature pointing to likely gene targets
for manipulation [18,19], employed omics-based metabolic engineering [20] or inverse metabolic
engineering [10], to highlight pathways that can be tested to improve production. These latter
approaches have successfully improved the total amount of protein carrying the desired glycan
structure, without a significant loss of total recombinant protein yield. Isocitrate lyase (IcL) is a key
enzyme in the glyoxylate pathway that cleaves isocitrate to succinate and glyoxylate. Through its
overexpression in E. coli, a three-fold increase was observed in glycosylation efficiency [20]. It was
theorised that utilisation of the glyoxylate pathway instead of the full citric acid cycle conserves carbons,
and these excess carbons could be used in the production of glycan precursors. Similarly, the ptsA
gene encoding for the phosphoenol-pyruvate (PEP) protein phosphotransferase system enzyme I was
overexpressed in E. coli cells, resulting in almost a seven-fold increase in the production of glycoprotein
AcrA [10]. PtsA is initially phosphorylated by PEP and subsequently transfers its newly acquired
phosphoryl group to a histidine phosphocarrier protein which in turn continues the cascade [21,22].
The pathway was discovered in E. coli and found to be involved in the uptake and phosphorylation
of a variety of sugars, including N-acetylglucosamine, which is potentially beneficial to the bacterial
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glycosylation process. In the same study, overexpression of dxs gave a 1.3-fold increase in glycosylation
efficiency. The dxs gene encodes for 1-deoxyxylulose-5-phosphate (DXP) synthase, which catalyses
the production of DXP from pyruvate and D-glyceraldehyde-3-phosphate (D-GAP) in a thiamine
diphosphate-dependent manner [23,24]. The production of DXP is deemed to be the rate-limiting
step in the mevalonate pathway of isoprenoid synthesis [25], but downstream of DXP synthesis, it
is involved in the production of a number of molecules including undecaprenyl phosphate (Und-P),
which acts as the bacterial lipid anchor on which the glycans are built. These modifications target
metabolic processes where carbon flux can be diverted from central carbon metabolism and re-directed
towards the recombinant glycosylation pathway, or enable efficient conversion of carbon without
compromising cellular growth rates.
In this study, the effect of the overexpression of these three genes (ptsA, icL and dxS), in
various combinations, were analysed using a lectin screen that detects cell surface representation
of glycans through the exploitation of the native E. coli O-antigen ligase, WaaL, in MC4100 E. coli
cells. Western blot analysis was conducted to determine the protein glycosylation efficiency and
relative glycoprotein production in the bacterial strain, CLM24, where waaL has been knocked out to
prevent cell surface representation of recombinant glycans [26]. The aim was to firstly characterise the
effect of the overexpression of these previously identified genes on glycan production, followed by
impacts on glycosylation efficiency. The bacterial exemplar N-glycoprotein, AcrA, was initially used
as it is the most understood target glycoprotein, together with the model bacterial N-glycosylation
machinery termed protein glycosylation pathway 2 (pgl2) [27]. To explore whether the engineered
cells could improve the glycosylation of an industrially relevant protein, IFN-α2b was also tested as a
target glycoprotein. IFN-α2b is a frequently used cytokine for therapeutic purposes and commercial
variants are produced in E. coli e.g., Grippferon® (Firn-M, Moscow, Russia) [28]. It contains a known
O-glycosylation site in a relatively unstructured region, and this was modified to enable bacterial
N-glycosylation.
2. Materials and Methods
All materials were purchased from Sigma-Aldrich (Dorset, UK), with working antibiotic
concentrations of 100 µg/mL ampicillin, 35 µg/mL chloramphenicol, and 35 µg/mL kanamycin
used where appropriate, unless stated otherwise.
2.1. PCR, DNA Cloning and Vectors
The strategy employed to overexpress the genes of interest was to place them under a constitutive
promoter on the same plasmid as the target protein. To achieve this, a new multiple cloning site (MCS)
was inserted into pEC(acrA). The MCS contained the necessary restriction sites to insert the three genes
of interest and was designed with the constitutive promoter, J23119, from the iGEM catalogue (Table
S1). This 35 bp promoter was placed upstream of the restriction sites required for insertion. Forward
primers used to amplify the genes of interest contained the Shine Dalgarno sequence, AGGAGG, and
a six base pair gap to ensure the ribosome binding site (RBS) was situated upstream of the start codon
(Table S2). Upon creation of the various constructs, plasmids were sent off for sequencing to confirm
insertion and to ensure that no PCR errors were incorporated.
PCR reactions: 98 ◦C for 3 min, 30 cycles of 30 s at 98 ◦C, 30 s at the annealing temperature of
the primer, and an extension step at 72 ◦C run at 1 kb per 30 s, extended depending on the size of the
fragment being amplified. A final extension step was also run at 72 ◦C for 10 min before cooling the
reaction to 4 ◦C.
Post amplification of the MCS, the reaction was subjected to agarose gel analysis, with the DNA
being extracted using a Qiagen® kit (Hilden, Germany) prior to digestion with EcoRI and XmaI at 37
◦C for 1 h. The target plasmid pEC (acrA) was also digested before insertion of the MCS using T4 ligase
(NEB) following the manufacturer’s protocol to create the pEC (acrA_MCS) plasmid. The three genes
to be inserted were amplified from the plasmids outlined in the aforementioned studies [10,20] and
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cloned into pEC (acrA_MCS) with the specific restriction enzymes that were required for the particular
inserts. The seven constructs were all validated with restriction digestion and sequence analysis prior
to transformations in the appropriate strains with pACYC (pgl2).
The amino acid sequence for an IFN-α2b with a C. jejuni glycosylation consensus sequence was
designed by locating a suitable region based on the crystal structure available in the PDB (1ITF).
The T corresponds to residue T106, an O-linked glycosylation site and due to being in a relatively
unstructured region on the protein, it was chosen as the site for modification. A glutamic acid (E) and
asparagine (N) were inserted at site 102 and 104, respectively, into the amino acid sequence using
the nucleotide sequence for IFN-α2b (NCBI sequence ID CAA23809.1), together with the pelB signal
sequence and a C-terminal hexa-his tag sequence (Supplementary Files). The subsequent sequence
was codon optimised, synthesised by DNA 2.0 and used to replace acrA in the pEC (acrA_MCS)
plasmid. A Western blot using a lectin peroxidase blot was used to test for glycosylation as described
previously [10].
2.2. Cell Surface Representation of Glycans
One mL of LB in a sterile 1.5 mL centrifuge tube was inoculated with the bacterial strain of
interest, and the appropriate antibiotics were added. Oxygen-limited growth took place overnight at
37 ◦C shaking at 180 rpm to limit cell density. The O.D at 600 nm was measured and cultures were
normalised down to 0.6 using sterile deionised water. The cells were then diluted by a factor of 1 in
75,000 using sterile deionised water to a final volume of 1 mL. One-hundred µL of the diluted cells
were plated out on LB agar with the appropriate antibiotics and left to incubate and grow aerobically
at 37 ◦C overnight. A piece of Protran™ nitrocellulose paper was cut to fit a petri dish and soaked in
the appropriate antibiotics for 5 min before being left to dry in a flow hood. The paper was placed over
the petri dish, making contact with the colonies and left to incubate for 3 h at 37 ◦C. The nitrocellulose
membrane was blocked in PBS containing 2% Tween 20 for 2 min at room temperature, before being
washed twice with PBS for 10 min. The membrane was incubated in PBS with 0.05% TWEEN® 20,
1 mM CaCl2, 1 mMMnCl2, 1 mMMgCl2, and 3 µg soybean agglutinin lectin peroxidase (specific for
GalNAc) for 16 h at 20 ◦C. The membrane was then washed twice in PBS for 10 min before detecting
and analysing the colonies using Immobilon™ chemiluminescent HRP substrate (Millipore) with
ImageQuant™ RT ECL (GE Healthcare, Chicago, IL, USA), fitted with a 16-bit CCD camera.
2.3. Colony Analysis
Images were analysed using version 7 of the ImageQuant software (GE Healthcare, Chicago, IL,
USA). Single colonies were selected and those in close proximity of another colony were disregarded
to ensure minimal contamination resulting from two colony selection. Pixel intensity and area were
calculated and corrected to remove background. Density measurements were tallied, the means plotted
and compared to the control.
2.4. Bacterial Growth and Protein Expression
The starter inoculum of the bacterial strains were cultured overnight at 37 ◦C, 180 rpm.
One-hundred-mL cultures of Luria Broth media were inoculated with 1 mL of the starter culture
and incubated at 37 ◦C, 180 rpm. At an optical density (O.D) of 0.5 at 600 nm, 0.2% (v/v) L-arabinose
was added to induce target protein expression through the araBAD promoter. No induction of the
pgl pACYC (pgl2) plasmid was necessary due to constitutive expression. Cells were then left to
incubate and express the protein for 4 h at the lower temperature of 30 ◦C 180 rpm in order to aid
in the expression of correctly folded protein and minimise growth. The final OD of the cultures was
measured and 40 OD units worth was harvested through centrifugation at 4 ◦C, 4500× g for 10 min.
The supernatant was discarded and the pellet stored at −20 ◦C.
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2.5. Periplasmic Protein Extraction
Protein pellets were thawed on ice and resuspended in 1 mL of periplasmic lysis buffer (20%
sucrose, 1 g/L lysozyme, 30 mM Tris-HCl pH 8.5, 1× Halt protease inhibitor complex (Thermo Fisher
Scientific, Massachusetts, MA, USA)) and extracted on ice for 2 h. Samples were centrifuged at 4500× g
at 4 ◦C for 10 min. The supernatant, representing the soluble periplasmic fraction, was collected and
the total protein quantity was measured using a Bradford protein assay.
2.6. SDS-PAGE and Western Blot Analysis
Five micrograms of periplasmic protein extract was added to 6 µLNuPAGE™LDS sample loading
buffer (4×) (Thermo Fisher Scientific, Massachusetts, MA, USA), 2.4 µL of sample reducing agent,
with sufficient water added to make a final volume of 24 µL. Samples were heated to 80 ◦C for 10 min
and left to cool to room temperature. Precast NuPAGE™Novex 4–12% Bis-Tris gels (Thermo Fisher
Scientific, Massachusetts, MA, USA) were loaded into the gel apparatus and the two chambers filled
with the required MOPS SDS buffer. Samples were loaded into the wells and the gel run for 1.5 h at
180 V. The gel was extracted from the cast and washed in deionised water. Proteins were transferred
to a nitrocellulose membrane using an iBlot® (Thermo Fisher Scientific, Massachusetts, MA, USA).
The membrane was subsequently blocked in blocking buffer (5% milk powder in Tris-Buffered Saline
(TBS) with 0.1% v/v Tween20) for 1 h at room temperature. Three × 10 min washes of the membrane
in TBS 0.1% Tween20 was followed by overnight incubation at 4 ◦C in blocking buffer with a His-tag
antibody (Abcam® Anti-6X His tag® (HRP), Cambridge, UK) (1:10,000). The excess unbound antibody
was washed off with 3 × 10 min washes in TBS 0.1% Tween20. The HRP linked antibody was detected
on the blot using 10 mL of TMB-Ultra blotting solution (Thermo Fisher Scientific, Massachusetts, MA,
USA) for 20 min. For the lectin peroxidase blot, the same procedure was followed except the antibody
was replaced with soybean agglutinin (SBA) lectin (specific for GalNAc) peroxidase as described
previously [10]. Pictures were captured using a 16-bit CCD camera. Images were analysed using Image
Studio Lite v5.2. Bands were highlighted and the pixel intensity and area calculated to obtain the
densitometry measurements with background correction factored into the analysis. Where applicable,
a quantified standard of His-tag purified aglycosylated AcrA was used to measure the amounts of
the target produced, as described previously [19]. Samples were run in triplicate and an unpaired
t-test with Welch’s correction (assuming both the populations do not have the same standard error)
was undertaken to look for statistically significant differences (P < 0.05). The quantification of total
glycoprotein per litre of pgl2 IFN generated in flask culture was calculated through the analysis of the
final OD of the culture and the amount of glycosylated target protein extracted from the periplasm
of 30 OD units of culture as a percentage of the total protein present in the same 30 OD of periplasm.
In brief, the final OD600 measurement of the culture was measured with 1 mL of OD600, 1.0 being
equal to 1 OD unit. Thirty OD units were harvested, the periplasmic protein extracted, quantified and
5 µg loaded onto a gel for western alongside 0.5 µg of aglycosylated, His tagged pure AcrA standard.
The target protein was quantified against the standard, and the amount of target protein present per
30 OD of periplasm was determined. This was then used to determine the total amount of target
glycoprotein present in 1 L of culture.
3. Results and Discussion
3.1. MC4100 Cell Surface Representation of Glycans
Constructs were transformed into E. coli MC4100 along with the protein glycosylation machinery
Pacyc (pgl2). As a positive control, the cell line MC4100 with pEC (acrA_MCS) pACYC (pgl2) was
created. For the negative control, just the pEC (acrA_MCS) plasmid was transformed into the cell
line MC4100. MC4100 was chosen because of the presence of the waaL gene. This gene expresses
an O-antigen ligase that can recognise the glycan as a potential substrate and attach it to a lipid A
core, which subsequently gets exported to the cell surface, placing the glycan on the extremity of the
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cell. By having this pathway intact and not inducing the expression of the target protein, it allows
the presentation of the glycans on the cell surface. This enabled semi-quantitative analysis of glycan
production through immunoblotting the surface of the cells with a lectin specific to the sugar residues
in the pgl2 glycan.
Cell surface representation of glycans produced by the various cell lines are shown in
Supplementary Files (Figure S1). Fifty-five single isolated colonies were analysed at random on each
plate and their densitometry compared to that of the positive control. From this, the glycan production
of each strain was measured and compared based on relative intensity (Figure 1). Although five of the
engineered strains expressed statistically significantly more glycans on their cell surface, changes were
very small. Of the combinations tested, the cells expressing both ptsA and icl had the biggest influence
on glycan production, but they only had a 6.4% increase (Figure S1B). However, cells expressing dxs
alone or in combination with icl had an inverse effect (Figure 1). The 3.2% increase observed with
pEC (acrA_ICL) was reduced to a negative 2.1% change when icl was over expressed in combination
with dxs in pEC (acrA_dxs_ICL). In subsequent experiments, a bacterial strain with a waaL deletion
was used so that glycans were transferred to the expressed target protein. This enabled us to analyse
whether the findings of the surface glycan screen were actually translated to overall glycoprotein
production and glycosylation efficiency.

 
Figure 1. Mean density measurements for colonies in positive control strain (AcrA is acrA with pgl2)
and engineered strains. Error bars represent the standard deviation of 55 colonies. Asterisks (*)
above the bars indicate strains of significant difference from the control (Unpaired t-test with Welch’s
correction, n = 3; P < 0.05).
Bioengineering 2019, 6, 27 7 of 13
3.2. Measuring Glycoprotein Production Capability
3.2.1. Expression of Glycosylated AcrA in E. coli Cells, CLM24
Constructs were transformed into E. coli CLM24, a strain that is waaL deficient, along with the
protein glycosylation machinery pACYC (pgl2). As a positive control, the cell line CLM24 with pEC
(acrA_MCS) pACYC (pgl2) was used. For the negative control, the pEC (acrA_MCS) plasmid was
transformed into cells. The bacteria were grown in culture and induced with L-arabinose to express
the target protein. SDS-PAGE and subsequent Western blotting was used to analyse production (using
an anti-His antibody), with the densitometry of the bands used to calculate the relative glycoprotein
production and glycosylation efficiency (Figure S2).
Figure 2 shows the relative glycosylation efficiency of the engineered strains. Some are represented
with an absence of data due to the lack of glycoprotein producing samples indicating a detrimental
effect on glycan transfer to the protein target. Of the seven combinations tested, three were shown to
have statistically different glycosylation efficiency when compared to the control. pEC (acrA_ptsA_ICL)
gave the highest glycosylation efficiency, with a 1.69-fold increase. Two of the other significant
strains, pEC (acrA_ptsA_dxs_ICL) and pEC (acrA_ptsA), caused a 1.48-fold and 1.27-fold increase in
efficiency, respectively.

Figure 2. Glycosylation efficiency of the strains expressing acrA, the metabolic engineering genes
and the pgl2 machinery. Cells without metabolic engineering of central carbon metabolism, CLM24
pEC(acrA) pACYC(pgl2), was included for a comparative control. Efficiency calculated through
measuring the density of aglycosylated and glycosylated bands of AcrA. “A” denotes acrA expression
and asterisks (*) above the bars indicate strains of significant difference from the control (Unpaired
t-test with Welch’s correction, n = 3; P < 0.05). AcrA is the control strain comprising of the target
protein gene (acrA) and glycosylation machinery contained in the pgl2 plasmid without any additional
metabolic engineering elements.
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Two of the constructs were detrimental towards the glycosylation process within the cell, as
no or few glycoprotein bands were observed on the Western blots. Both of the affected strains over
expressed dxs (either alone or with icl). Overexpression of dxs reduces glycosylation efficiency when
combined with the increased expression of both ptsA and icl (expressing all three ptsA, dxs and icl
genes), compared to strains engineered with ptsA and icl alone. Of the seven combinations tested,
the most efficient combination in terms of glycosylation efficiency was ptsA and icL, which raised
efficiency from 24.6% to 41.6%. This 1.69-fold increase from the control was reduced to a 1.47-fold
increase with the further overexpression of dxs and highlights its negative impact. The reduction of
efficiency from 31.2% in pEC (acrA_ptsA) to 24.8% in pEC (acrA_ptsA_dxs) and the negative effect
from dxs addition in pEC (acrA_dxs_ICL), whereby its inclusion inhibited the cells ability to produce
detectable glycoproteins in two of the three biological replicates, adds to this argument.
The cell response to overexpression of dxs was unexpected, as this was previously shown to
increase glycosylation efficiency 1.3-fold in a similar background strain, although with a different
glycan structure [10]. Moreover, the growth rates of the strains tested did not differ significantly
(data not shown). In our previous study, although overexpression of dxs showed a slight negative
impact on the growth rate, this was not statistically significant. Interestingly, it did show a 1.6-fold
reduction in recombinant protein yields [10]. DXP is used in isoprenoid biosynthesis, which is known
to be involved in a wide variety of biological functions. It is therefore expected that fluxes within
the isoprenoid metabolic network are tightly regulated, temporally and spatially. This makes it very
difficult to dissect the mechanistic impact of DXP overexpression in terms of growth and protein
production. When dxs was over expressed with a stronger promoter system (synthetic trc promoter),
as in a previous study [29], growth yield (this was based on final OD) was severely inhibited, and it
is hypothesised that this may be due to a drain on glycolytic intermediates necessary for balanced
growth. It could be that if induced more moderately, growth is not impacted significantly, but when
switched to protein production phase, the intermediates for protein production are affected.
In another study, it was elegantly demonstrated how promoter strength can affect the impact
of dxs on downstream metabolic pathways in E. coli [30]. In the study, dxs was identified as the first
enzymatic step in the production of a carotenoid, and in a wild type E. coli strain, increasing promoter
strengths led to elevated carotenoid expression only to a certain level. It was hypothesised that other
enzymes in the pathway become rate-limiting as well as cause toxic accumulation of the dxs product,
DXP. In contrast, a strain engineered to overexpress these downstream enzymes showed a linear
increase in carotenoid expression as promoter strengths for dxs were increased [30]. This implies that
an E. coli glycoprotein platform strain would require enzymes downstream of dxs to be optimised to
see the benefit of dxs overexpression. A map illustrating metabolic pathways downstream of dxs as
well as the role of icl in central carbon metabolism is shown in Supplementary Files (Figure S3).
3.2.2. Expression of Glycosylated IFNα2b in E. coli Cells, CLM24
Three of the engineered cell lines are capable of improving the glycosylation efficiency of
AcrA, and this is based on the hypothesis that the quantity of glycan precursors are limited during
recombinant glycoprotein induction. Therefore, we expected that other glycoprotein targets should
also have higher sugar occupancy levels in the engineered strains. We selected IFNα2b as this is an
industrially-relevant, therapeutic protein. IFNα2b is a relatively small protein at 23.7 kDa. A single
bacterial N-glycosylation consensus sequence of EVNVT was engineered from amino acid 102 to 106
(Figure 3). Human IFN fragments have been expressed in E. coli previously, including transport to
the periplasmic space [31,32]. A Western blot using soyabean agglutinin lectin and lectin peroxidase
was used to detect a glycosylated protein band to ensure the site was accessible for the C. jejuni
oligosaccharyltransferase PglB (Figure 3).
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Figure 3. N-glycosylation of IFN-α2b in E. coli (left: crystal structure. GVGVT amino acid sequence was
changed to EVNVT. In PDB, 1ITF GVGVT is at position 102–106. The T corresponds to the O-linked
glycosylation site as residue T106 (The 102GVGV105 is marked in red and T106 in green); right: lectin
peroxidase blot with AcrA control.
As Figure 4 shows, the glycosylation efficiency of IFNα2b in control cells pEC (IFN_MCS) pACYC
(pgl2) was approximately 10.9% (Western blots shown in Figure S4). However, all engineered cells
showed statistically significant improvements in the ratio of protein which carried the hexasaccharide
glycan structure. pEC (IFN_ptsA) was the highest with 24.5% glycosylated. pEC (IFN_ptsA_ICL) and
pEC (IFN_ptsA_ICL_dxs) glycosylated with 22.6% and 22.8% efficiency, respectively.

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Figure 4. Glycosylation efficiency of the strains expressing IFN-α2b, the metabolic engineering genes
and the pgl2 machinery. CLM24 pEC (IFN-α2b) pACYC (pgl2) is included for a comparative control.
Efficiency was calculated through measuring the density of glycosylated and glycosylated bands of
IFN-α2b. “I” denotes IFN-α2b expression and asterisks (*) above the bars indicate strains of significant
difference from the control (Unpaired t-test with Welch’s correction, n = 3; P < 0.05).
We also quantified total IFN-α2b glycoprotein due to its industrial relevance, and pEC
(IFN_ptsA_ICL) pACYC (pgl2) cells were the largest producer, with 882.9 µg L−1 compared to 351 µg
L−1 in the control (Figure 5). The need to optimise the expression of dxs was again evident in these
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strains, but the successful improvement in N-glycosylation capability through overexpression of ptsA
and icl was evident.

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Figure 5. Average µg glycoprotein per litre of cell culture expressing IFN-α2b along with the metabolic
engineering genes and the pgl2 machinery. CLM24 pEC (IFN-α2b) pACYC (pgl2) is included for a
comparative control. Quantity was calculated through measuring the density of glycosylated bands of
IFN-α2b compared to a loading control of 0.5 µg of purified AcrA. “I” denotes IFN-α2b expression and
asterisks (*) above the bars indicate strains of significant difference from the control (Unpaired t-test
with Welch’s correction, n = 3; P < 0.05).
Variations in glycosylation efficiency in different proteins, for example, AcrA and IFN-α2b, are
expected. These proteins are expressed to different levels and have very different structures, potentially
affecting the accessibility of the PglB oligosaccharyltransferase. Moreover, AcrA has two bacterial
N-glycosylation sites, N123 and N273, where the nitrogen on asparagine acts as the site for covalent
attachment to the glycan, compared to just one site engineered into IFN-α2b at N104. Both the
construction of glycans through glycosidic bonds and attachment of the hexasaccharide construct
to polypeptide backbones requires energy in the form of ATP [33] and, therefore, less sites would
reduce energy demands on the cell. However, both target proteins showed higher glycosylation
efficiency when both ptsA and icl were over expressed. As suggested previously, the enhanced uptake
and phosphorylation of sugars from the media is beneficial for an E. coli glycoprotein production
strain, providing precursors for glycan construction. Moreover, using the strains constructed for this
study, further conservation of carbon through increased flux through the glyoxylate pathway is a
complementary modification to the cell. Unexpectedly, overexpression of dxs was detrimental here,
even eliminating glycoprotein detection completely in some strains. Although it has been hypothesised
that phenotypes related to increased dxs expression require similar optimisation of associated pathway
enzymes, dxs is involved in isoprenoid production and therefore is used in diverse cellular processes
beyond Und-P production. Although Und-P abundance could be a bottleneck in N-glycosylation,
further studies would need to be undertaken to evidence this prior to identifying a gene target or
tuning dxs expression that can work in tandem with ptsA and icl overexpression.
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4. Conclusions
The physiology and genetics of E. coli are the most understood of all prokaryotic host cell factories
for the production of recombinant proteins. Although the addition of glycans to proteins is not a
native process in E. coli, there are advantages of incorporating this capability into the system, such as
improving the stability of industrial enzymes through to diagnostic applications. Little is known about
how the Campylobacter jejuni N-glycosylation system impacts on metabolism in E. coli, but here we
aimed to combine gene modification targets from previous studies, based on the hypothesis that central
carbon metabolism requires optimisation to improve glycosylation efficiency. Although combining the
overexpression of genes involved in sugar uptake and phosphorylation with pathways that enable
carbon conservation did not show large differences in glycan precursor production through a cell
surface display screen, significant increases in glycosylation efficiency on recombinant proteins were
revealed. AcrA and IFNα2b glycosylation increased 1.69-fold and 2.2-fold, respectively. However,
not all modifications were positive (dxs overexpression), highlighting the need to test multiple cell
engineering targets together and also the requirement for tuning the overexpression of individual
genes for optimisations, providing a more comprehensive understanding of cellular constraints.
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